Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors

Clinical Cancer Research

Volumn 9, Issue 11, 2003, Pages 4247-4254

  Heimberger, Amy B ^a   Crotty, Laura E ^b   Archer, Gary E ^b   Hess, Kenneth R ^a   Wikstrand, Carol J ^b   Friedman, Allan H ^b   Friedman, Henry S ^b   Bigner, Darell D ^b   Sampson, John H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; VACCINATION;

ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOCYANIN; LYMPHOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPLEEN; SURVIVAL RATE; TIME FACTORS;

EID: 0141790037     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ekstrand, A., Sugawa, N., James, C., and Collins, V. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA, 89: 4309-4313, 1992.
2. Humphrey, P., Wong, A. J., Vogelstein, B., Friedman, H. S., Werner, M. H., Bigner, D. D., and Bigner, S. H. Amplification and expression of the epidermal growth receptor gene in human glioma xenografts. Cancer Res., 48: 2231-2238, 1988.
3. Batra, S. K., Castelino-Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., and Bigner, D. D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvlII gene. Cell Growth Differ., 6: 1251-1259, 1995.
4. Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., and Huang, H. J. S. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA, 91: 7727-7731, 1994.
5. Furnari, F. B., Huang, H. J., and Cavenee, W. K. Molecular biology of malignant degeneration of astrocytoma. Pediatr. Neurosurg., 24: 41-49, 1996.
6. Wikstrand, C., Hale, L. P., Batra, S. K., Hill, L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N., Reist, C. J., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res., 55: 3140-3148, 1995.
7. Ehrlich, P. Collected Studies on Immunity. New York: Wiley, 1906.
8. Wikstrand, C. J., and Bigner, D. D. Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. J. Neuroimmunol., 1: 249-260, 1981.
9. Sampson, J. H., Crotty, L. E., Lee, S., Archer, G. E., Ashley, D. M., Wikstrand, C. J., Hale, L. P., Small, C., Dranoff, G., Friedman, A. H., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. USA, 97: 7503-7508, 2000.
10. Heimberger, A. B., Archer, G. E., Crotty, L. E., McLendon, R. E., Friedman, A. H., Friedman, H. S., Bigner, D. D., and Sampson, J. H. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery, 50: 158-166, 2002.
11. Sampson, J. H., Archer, G. E., Ashley, D. M., Fuchs, H. E., Hale, L. P., Dranoff, G., and Bigner, D. D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA, 93: 10399-10404, 1996.
12. Kurtzberg, J., and Hershfield, M. S. Determinants of deoxyadenosine toxicity in hybrids between human T- and B-lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia. Cancer Res., 45: 1579-1586, 1985.
13. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. Current Protocols in Immunology. New York: Green & Wiley Interscience, 1994.
14. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
15. Liau, L. M., Black, K. L., Prins, R. M., Sykes, S. N., DiPatre, P. L., Cloughesy, T. F., Becker, D. P., and Bronstein, J. M. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg., 90: 1115-1124, 1999.
16. Plautz, G. E., Touhalisky, J. E., and Shu, S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell. Immunol., 178: 101-107, 1997.
17. Moscatello, D. K., Ramirez, G., and Wong, A. J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy for tumors. Cancer Res., 57: 1419-1424, 1997.
18. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (Lond.), 400: 173-177, 1999.
19. Bard, F., Cannon, C., Barbour, R., Burke, R-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 6: 916-919, 2000.
20. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (Lond.), 408: 982-985, 2000.
21. Adams, D. O., Hall, T., Steplewski, Z., and Koprowski, H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA, 81: 3506-3510, 1984.
22. Fanger, M. W., Shen, L., Graziano, R. F., and Guyre, P. M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today, 10: 92-99, 1989.
23. Herlyn, D., and Koprowski, H. IgG2a monoclonal antibodies inhibit tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA, 79: 4761-4765, 1982.
24. Van Spriel, A. B., Leusen, J. H. W., van Egmond, M., Dijkman, H. B. P. M., Assmann, K. J. M., Mayada, T. N., and van de Winkel, G. J. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood, 97: 2478-2486, 2001.
25. Ulvestad, E., Williams, K., Matre, R., Nyland, H., Olivier, A., and Antel, J. Fc receptors for IgG on cultured human microglia mediate cytotoxicity and phagocytosis of antibody-coated targets. J. Neuropathol. Exp. Neurol., 53: 27-36, 1994.
26. Nitta, T., Yagita, H., Sato, K., and Okumura, K. Expression of Fc γ receptors on astroglial cell lines and their role in the central nervous system. Neurosurgery, 31: 83-87, 1992.
27. Machulla, H. K. G., Steinborn, F., Schaaf, A., Heidecke, V., and Rainov, N. G. Brain glioma and human leukocyte antigens (HLA): is there an association. J. Neurooncol., 52: 253-261, 2001.